van Vollenhoven R F, Engleman E G, McGuire J L
Division of Immunology and Rheumatology, Stanford University Medical Center, CA 94305, USA.
Arthritis Rheum. 1995 Dec;38(12):1826-31. doi: 10.1002/art.1780381216.
To determine if dehydroepiandrosterone (DHEA) is beneficial in the treatment of systemic lupus erythematosus (SLE).
In a double-blind, placebo-controlled, randomized trial, 28 female patients with mild to moderate SLE were given DHEA 200 mg/day or placebo for 3 months. Outcomes included the SLE Disease Activity Index (SLEDAI) score, patient's and physician's overall assessments of disease activity, and concurrent corticosteroid dosages (which were adjusted as clinically indicated).
In the patients who were receiving DHEA, the SLEDAI score, patient's and physician's overall assessment of disease activity, and concurrent prednisone dosage decreased, while in the patients taking placebo, small increases were seen. The difference in patient's assessment between the groups was statistically significant (P = 0.022, adjusted). Lupus flares occurred more frequently in the placebo group (P = 0.053). Mild acne was a frequent side effect of DHEA.
DHEA may be useful as a therapeutic agent for the treatment of mild to moderate SLE. Further studies of DHEA in the treatment of SLE are warranted.
确定脱氢表雄酮（DHEA）对系统性红斑狼疮（SLE）治疗是否有益。
在一项双盲、安慰剂对照、随机试验中，28例轻至中度SLE女性患者接受每日200毫克DHEA或安慰剂治疗3个月。结果包括SLE疾病活动指数（SLEDAI）评分、患者和医生对疾病活动的总体评估以及同时使用的皮质类固醇剂量（根据临床指征进行调整）。
接受DHEA治疗的患者中，SLEDAI评分、患者和医生对疾病活动的总体评估以及同时使用的泼尼松剂量均下降，而服用安慰剂的患者则有小幅上升。两组患者评估的差异具有统计学意义（P = 0.022，校正后）。安慰剂组狼疮发作更频繁（P = 0.053）。轻度痤疮是DHEA常见的副作用。
DHEA可能作为治疗轻至中度SLE的治疗药物。有必要对DHEA治疗SLE进行进一步研究。
